Dr Christoph Franz has been elected as the new chairman at Roche.
At the recent annual general meeting, Dr Christoph Franz was elected as the new chairman of the board at Roche, winning 99.8% of the vote and moving into the top seat after three years as a board member.
Dr Franz will take over the position from outgoing chairman Dr Franz Hurner, who leaves the company after two decades with Roche and spoke positively about the company’s prospects.
“The company is very well positioned for the future,” said Dr Hurner. “I am convinced that Christoph Franz as the new chairman will continue Roche’s success story together with the board and the executive committee.”
During the general meeting, the board members also voted to authorise a 6% rise in the gross dividend for the past financial year, making 2013 the 27th consecutive year for a rise.
Roche also recorded a 6% year-on-year rise in sales during the past financial year, an achievement credited to the success of products such as Avastin, Lucentis and MabThera.